Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and PreventionAccesswire • Tuesday
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceAccesswire • 08/27/24
Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder LetterAccesswire • 08/26/24
Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing SafetyAccesswire • 08/19/24
Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024Accesswire • 08/12/24
Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care TestingAccesswire • 08/09/24
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS DrugAccesswire • 07/23/24
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDAAccesswire • 06/14/24
Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential MarketAccesswire • 05/15/24
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 SymptomsAccesswire • 02/05/24
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of SmellAccesswire • 12/26/23
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss PharmaceuticalAccesswire • 11/28/23
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDAAccesswire • 11/21/23